Biosimilar Filgrastim Safety Confirmed in Analysis

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 Phase 3 breast cancer studies from the United States and Europe.

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply